NR3C2 and diabetic kidney disease: The ARTS, ARTS-HF, and ARTS-DN studies have validated its advantages for heart failure and diabetic nephropathy patients while emphasizing its superior safety profile compared to steroidal mineralocorticoid receptor antagonists, particularly in terms of hyperkalemia.